Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (77,224)	$ (84,549)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation, amortization and accretion	2,489	2,707
Stock-based compensation expense	5,715	3,763
Loss on extinguishment of debt, net	765	830
(Gain) Loss on sale, abandonment/disposal or impairment of property and equipment	(10)	179
(Gain) Loss on foreign currency translation	(3,107)	12,077
Gain on purchase commitments		(215)
Interest on note payable to related party	3,345	2,608
Change in fair value of warrant liability		(5,488)
Write-off of inventory	1,792	1,793
Other, net	106	44
Changes in operating assets and liabilities:
Accounts receivable, net	(74)	(1,502)
Receivable from Sanofi		30,557
Inventory	(1,920)	(2,591)
Deferred costs from commercial product sales		(234)
Prepaid expenses and other current assets	(5)	1,303
Other assets	200	166
Accounts payable	(1,169)	2,099
Accrued expenses and other current liabilities	560	2,889
Deferred revenue		(398)
Deferred payments from collaborations	11,983	(187)
Recognized loss on purchase commitments	(6,165)	(648)
Net cash used in operating activities	(62,719)	(34,797)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net proceeds from sale of asset held for sale		16,651
Proceeds from sale of property and equipment	10	24
Net cash provided by investing activities	10	16,675
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from direct placement of common stock	28,000
Issuance cost associated with direct placement	(1,610)
Principal payments on facility financing obligation	(2,000)	(4,000)
Borrowings on note payable to related party		19,429
Payment of employment taxes related to vested restricted stock units	(184)	(110)
Proceeds from issuance of common stock pursuant to at-the-market issuance	819
Issuance cost of at-the-market transactions	(33)
Proceeds from market price stock purchase plan	335
Net cash provided by financing activities	25,327	15,319
NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(37,382)	(2,803)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	48,355	22,895
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	10,973	20,092
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash, net of amounts capitalized	2,895	6,373
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payment of note obligations through common stock issuance	42,912	11,000
Payment of note payable to related party through common stock issuance	8,160
Capitalization of interest on note payable to related party		10,716
Accrued but unpaid debt issuance costs	$ 146
Reclassification of warrant liability to Additional paid-in capital		$ 1,893